{"id":"dotinurad","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Solute carrier family 22 member 12","category":"target"},{"label":"SLC22A12","category":"gene"},{"label":"SLC22A8","category":"gene"},{"label":"SLC22A6","category":"gene"},{"label":"Active","category":"status"},{"label":"Gout","category":"indication"},{"label":"Hyperuricemia","category":"indication"},{"label":"Fuji Yakuhin","category":"company"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Gout Suppressants","category":"pharmacology"},{"label":"Uricosuric Agents","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Fuji Yakuhin","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DOTINURAD","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:17:02.790862+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:17:08.287785+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DOTINURAD","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:17:08.575336+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Solute carrier family 22 member 12 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:17:09.627264+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4594446/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:17:09.280409+00:00"}},"allNames":"urece","offLabel":[],"synonyms":["dotinurad","urece","FYU-981"],"timeline":[{"date":"2020-01-23","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Fuji Yakuhin)"}],"approvals":[{"date":"2020-01-23","orphan":false,"company":"Fuji Yakuhin","regulator":"PMDA"}],"brandName":"Urece","ecosystem":[{"indication":"Gout","otherDrugs":[{"name":"allopurinol","slug":"allopurinol","company":"Prometheus Labs"},{"name":"colchicine","slug":"colchicine","company":"Merck"},{"name":"indomethacin","slug":"indomethacin","company":""},{"name":"naproxen","slug":"naproxen","company":"Roche Palo"}],"globalPrevalence":41000000},{"indication":"Hyperuricemia","otherDrugs":[{"name":"allopurinol","slug":"allopurinol","company":"Prometheus Labs"},{"name":"febuxostat","slug":"febuxostat","company":"Takeda Pharms Usa"},{"name":"lesinurad","slug":"lesinurad","company":"Ardea Biosciences Inc"},{"name":"probenecid","slug":"probenecid","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Solute carrier family 22 member 12","targets":[{"gene":"SLC22A12","source":"DrugCentral","target":"Solute carrier family 22 member 12","protein":"Solute carrier family 22 member 12"},{"gene":"SLC22A8","source":"DrugCentral","target":"Solute carrier family 22 member 8","protein":"Solute carrier family 22 member 8"},{"gene":"SLC22A6","source":"DrugCentral","target":"Solute carrier family 22 member 6","protein":"Solute carrier family 22 member 6"},{"gene":"ABCG2","source":"DrugCentral","target":"ATP-binding cassette sub-family G member 2","protein":"ATP-binding cassette sub-family G member 2"},{"gene":"CYP2C9","source":"DrugCentral","target":"Cytochrome P450 2C9","protein":"Cytochrome P450 2C9"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Urece specifically targets the solute carrier family 22 member 12 (SLC22A12), a protein responsible for the reabsorption of uric acid in the kidneys. By inhibiting this protein, Urece reduces the reabsorption of uric acid, leading to increased excretion in the urine and decreased levels in the blood."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5425","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DOTINURAD","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DOTINURAD","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:50:03.444768","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:17:10.930205+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"alectinib","drugSlug":"alectinib","fdaApproval":"2015-12-11","patentExpiry":"May 29, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-target"},{"drugName":"atazanavir","drugSlug":"atazanavir","fdaApproval":"2003-06-20","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"atorvastatin","drugSlug":"atorvastatin","fdaApproval":"1996-12-17","patentExpiry":"Jun 7, 2037","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"atovaquone","drugSlug":"atovaquone","fdaApproval":"1992-11-25","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"avapritinib","drugSlug":"avapritinib","fdaApproval":"2020-01-09","patentExpiry":"Oct 15, 2034","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"azathioprine","drugSlug":"azathioprine","fdaApproval":"1968-03-20","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"bosutinib","drugSlug":"bosutinib","fdaApproval":"2012-09-04","patentExpiry":"Nov 23, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"candesartan cilexetil","drugSlug":"candesartan-cilexetil","fdaApproval":"1998-06-04","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"caspofungin","drugSlug":"caspofungin","fdaApproval":"2001-01-26","patentExpiry":"Dec 21, 2032","patentStatus":"Patent protected","relationship":"same-target"}],"genericName":"dotinurad","indications":{"approved":[{"name":"Gout","source":"DrugCentral","snomedId":90560007,"regulator":"FDA","usPrevalence":9200000,"globalPrevalence":41000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"},{"name":"Hyperuricemia","source":"DrugCentral","snomedId":35885006,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"alectinib","brandName":"alectinib","genericName":"alectinib","approvalYear":"2015","relationship":"same-target"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-target"},{"drugId":"atazanavir","brandName":"atazanavir","genericName":"atazanavir","approvalYear":"2003","relationship":"same-target"},{"drugId":"atorvastatin","brandName":"atorvastatin","genericName":"atorvastatin","approvalYear":"1996","relationship":"same-target"},{"drugId":"atovaquone","brandName":"atovaquone","genericName":"atovaquone","approvalYear":"1992","relationship":"same-target"},{"drugId":"avapritinib","brandName":"avapritinib","genericName":"avapritinib","approvalYear":"2020","relationship":"same-target"},{"drugId":"azathioprine","brandName":"azathioprine","genericName":"azathioprine","approvalYear":"1968","relationship":"same-target"},{"drugId":"bosutinib","brandName":"bosutinib","genericName":"bosutinib","approvalYear":"2012","relationship":"same-target"},{"drugId":"candesartan-cilexetil","brandName":"candesartan cilexetil","genericName":"candesartan cilexetil","approvalYear":"1998","relationship":"same-target"},{"drugId":"caspofungin","brandName":"caspofungin","genericName":"caspofungin","approvalYear":"2001","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07089888","phase":"PHASE3","title":"A Study of Dotinurad Versus Allopurinol in Tophaceous Gout","status":"RECRUITING","sponsor":"Crystalys Therapeutics","startDate":"2025-08-04","conditions":["Tophaceous Gout"],"enrollment":250,"completionDate":"2027-12-31"},{"nctId":"NCT07089875","phase":"PHASE3","title":"A Study of Dotinurad Versus Allopurinol in Participants With Gout","status":"RECRUITING","sponsor":"Crystalys Therapeutics","startDate":"2025-08-01","conditions":["Gout"],"enrollment":500,"completionDate":"2027-11-29"},{"nctId":"NCT06834230","phase":"PHASE4","title":"Effect of Dotinurad in Hyperuricemia With Hypertension","status":"RECRUITING","sponsor":"Saga University","startDate":"2025-03-28","conditions":["Hyperuricemia or Gout","Hypertension"],"enrollment":360,"completionDate":"2030-03-31"},{"nctId":"NCT05007392","phase":"PHASE3","title":"A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2021-12-21","conditions":["Gout"],"enrollment":451,"completionDate":"2023-06-14"},{"nctId":"NCT06056570","phase":"PHASE1,PHASE2","title":"Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia","status":"COMPLETED","sponsor":"Urica Therapeutics Inc.","startDate":"2023-10-04","conditions":["Gout","Hyperuricemia"],"enrollment":20,"completionDate":"2024-07-09"},{"nctId":"NCT05278676","phase":"PHASE1","title":"A Single and Multiple Dose Study of Dotinurad in Chinese Healthy Participants","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2022-07-01","conditions":["Healthy Volunteers"],"enrollment":26,"completionDate":"2022-12-13"},{"nctId":"NCT03350386","phase":"PHASE1","title":"Drug-drug Interaction Study of FYU-981 and Oxaprozin","status":"COMPLETED","sponsor":"Mochida Pharmaceutical Company, Ltd.","startDate":"2017-11-02","conditions":["Healthy"],"enrollment":12,"completionDate":"2017-12-05"},{"nctId":"NCT03006445","phase":"PHASE3","title":"Study of FYU-981 in Hyperuricemia With or Without Gout","status":"COMPLETED","sponsor":"Fuji Yakuhin Co., Ltd.","startDate":"2016-12","conditions":["Hyperuricemia With or Without Gout"],"enrollment":330,"completionDate":"2018-10-24"},{"nctId":"NCT03100318","phase":"PHASE3","title":"Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout","status":"COMPLETED","sponsor":"Fuji Yakuhin Co., Ltd.","startDate":"2017-04-01","conditions":["Hyperuricemia With or Without Gout"],"enrollment":201,"completionDate":"2018-08-31"},{"nctId":"NCT03372200","phase":"PHASE3","title":"Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout","status":"COMPLETED","sponsor":"Mochida Pharmaceutical Company, Ltd.","startDate":"2018-01-09","conditions":["Hyperuricemia With or Without Gout"],"enrollment":203,"completionDate":"2018-07-05"},{"nctId":"NCT03375632","phase":"PHASE1","title":"Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)","status":"COMPLETED","sponsor":"Mochida Pharmaceutical Company, Ltd.","startDate":"2018-01-04","conditions":["Hyperuricemia With or Without Gout"],"enrollment":26,"completionDate":"2018-06-05"},{"nctId":"NCT03306667","phase":"PHASE1","title":"Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency)","status":"COMPLETED","sponsor":"Mochida Pharmaceutical Company, Ltd.","startDate":"2017-10-06","conditions":["Hepatic Insufficiency","Healthy"],"enrollment":24,"completionDate":"2018-06-25"},{"nctId":"NCT02837198","phase":"PHASE2","title":"Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)","status":"COMPLETED","sponsor":"Fuji Yakuhin Co., Ltd.","startDate":"2016-07","conditions":["Hyperuricemia"],"enrollment":24,"completionDate":"2018-03"},{"nctId":"NCT03350373","phase":"PHASE1","title":"Clinical Pharmacology of FYU-981 (Final Formulation)","status":"COMPLETED","sponsor":"Mochida Pharmaceutical Company, Ltd.","startDate":"2017-11-06","conditions":["Healthy"],"enrollment":12,"completionDate":"2017-11-29"},{"nctId":"NCT02515864","phase":"PHASE2","title":"Clinical Pharmacology of FYU-981 (Effect on QT/QTc Interval)","status":"COMPLETED","sponsor":"Fuji Yakuhin Co., Ltd.","startDate":"2015-08","conditions":["Healthy"],"enrollment":48,"completionDate":"2016-11"},{"nctId":"NCT02416167","phase":"PHASE2","title":"Study of FYU-981 in Hyperuricemia With or Without Gout","status":"COMPLETED","sponsor":"Fuji Yakuhin Co., Ltd.","startDate":"2015-05","conditions":["Hyperuricemia"],"enrollment":200,"completionDate":"2016-11"},{"nctId":"NCT02347046","phase":"PHASE1","title":"Clinical Pharmacology of FYU-981 (Subjects With Renal Insufficiency)","status":"COMPLETED","sponsor":"Fuji Yakuhin Co., Ltd.","startDate":"2015-01","conditions":["Renal Insufficiency","Healthy"],"enrollment":18,"completionDate":"2015-03"},{"nctId":"NCT02348307","phase":"PHASE1","title":"Single Dose Phase I Study of FYU-981","status":"COMPLETED","sponsor":"Fuji Yakuhin Co., Ltd.","startDate":"2013-03","conditions":["Healthy"],"enrollment":54,"completionDate":"2013-08"},{"nctId":"NCT02348333","phase":"PHASE1","title":"Repeated Dose Phase I Study of FYU-981","status":"COMPLETED","sponsor":"Fuji Yakuhin Co., Ltd.","startDate":"2013-09","conditions":["Healthy"],"enrollment":18,"completionDate":"2013-12"},{"nctId":"NCT02344875","phase":"PHASE1","title":"Clinical Pharmacology of FYU-981 (Elder Subjects)","status":"COMPLETED","sponsor":"Fuji Yakuhin Co., Ltd.","startDate":"2014-05","conditions":["Healthy"],"enrollment":24,"completionDate":"2014-07"},{"nctId":"NCT02344862","phase":"PHASE2","title":"Study of FYU-981 in Hyperuricemia With or Without Gout","status":"COMPLETED","sponsor":"Fuji Yakuhin Co., Ltd.","startDate":"2014-01","conditions":["Hyperuricemia"],"enrollment":80,"completionDate":"2014-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"305EB53128","INN_ID":"10438","UMLSCUI":"C5238059","chemblId":"CHEMBL4594446","ChEMBL_ID":"CHEMBL4594446","KEGG_DRUG":"D11071","DRUGBANK_ID":"DB16145","PUBCHEM_CID":"51349053","IUPHAR_LIGAND_ID":"11389","MESH_SUPPLEMENTAL_RECORD_UI":"C000706811"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Fuji Yakuhin","relationship":"Current Owner"}],"publicationCount":74,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Fuji Yakuhin","companyId":"fuji-yakuhin","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2020-01-23T00:00:00.000Z","mah":"Fuji Yakuhin","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:17:10.930205+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}